BR0010014A - Pharmaceutical composition comprising an inositol and a metal ion to improve insulin sensitivity and glucose metabolism - Google Patents

Pharmaceutical composition comprising an inositol and a metal ion to improve insulin sensitivity and glucose metabolism

Info

Publication number
BR0010014A
BR0010014A BR0010014-5A BR0010014A BR0010014A BR 0010014 A BR0010014 A BR 0010014A BR 0010014 A BR0010014 A BR 0010014A BR 0010014 A BR0010014 A BR 0010014A
Authority
BR
Brazil
Prior art keywords
inositol
metal ion
insulin sensitivity
glucose metabolism
pharmaceutical composition
Prior art date
Application number
BR0010014-5A
Other languages
Portuguese (pt)
Inventor
Manasses C Fonteles
Original Assignee
Insmed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Pharm Inc filed Critical Insmed Pharm Inc
Publication of BR0010014A publication Critical patent/BR0010014A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA COMPREENDENDO UM INOSITOL E UM ìON DE METAL PARA MELHORAR SENSIBILIDADE à INSULINA E METABOLISMO DE GLUCOSE". A presente invenção refere-se a composições e métodos para aumentar a sensibilidade à insulina e/ ou aumentar o metabolismo de glucose em mamíferos, particularmente humanos. As composições da presente invenção contêm (i) uma fonte de um íon de metal polivalente, como magnésio, manganês, cromo, vanádio e zinco, e (ii) um inositol, como D-quiro-inositol, ou um derivado ou metabólito de um inositol, como D-3-O-metil-quiro-inositol."PHARMACEUTICAL COMPOSITION UNDERSTANDING INOSITOL AND METAL ION TO IMPROVE INSULIN SENSITIVITY AND GLUCOSE METABOLISM". The present invention relates to compositions and methods for increasing insulin sensitivity and / or increasing glucose metabolism in mammals, particularly humans. The compositions of the present invention contain (i) a source of a polyvalent metal ion, such as magnesium, manganese, chromium, vanadium and zinc, and (ii) an inositol, such as D-chiro-inositol, or a derivative or metabolite of a inositol, such as D-3-O-methyl-chiro-inositol.

BR0010014-5A 1999-04-27 2000-04-27 Pharmaceutical composition comprising an inositol and a metal ion to improve insulin sensitivity and glucose metabolism BR0010014A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13123199P 1999-04-27 1999-04-27
PCT/US2000/011196 WO2000064454A2 (en) 1999-04-27 2000-04-27 Pharmaceutical composition comprising an inositol and a metal ion for improving insulin sensitivity and glucose metabolism

Publications (1)

Publication Number Publication Date
BR0010014A true BR0010014A (en) 2002-01-15

Family

ID=22448518

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010014-5A BR0010014A (en) 1999-04-27 2000-04-27 Pharmaceutical composition comprising an inositol and a metal ion to improve insulin sensitivity and glucose metabolism

Country Status (6)

Country Link
EP (1) EP1173188A2 (en)
JP (1) JP2002542295A (en)
AU (1) AU4802800A (en)
BR (1) BR0010014A (en)
CA (1) CA2371055A1 (en)
WO (1) WO2000064454A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5277000A (en) 1999-05-20 2000-12-12 Humanetics Corporation Stimulating transport of glucose into animal tissue by the administration of pinitol
WO2002036127A2 (en) * 2000-10-31 2002-05-10 Nutrition 21, Inc. Methods and compositions for the treatment of polycystic ovary syndrome with chromium complexes
ITMI20110445A1 (en) * 2011-03-22 2012-09-23 Lo Li Pharma Srl PHARMACEUTICAL FORMULATION INCLUDING INOSITOLO.
CN106659739B (en) 2014-08-08 2021-06-18 雀巢产品有限公司 Combination of vitamin D and zinc and use thereof
JP7127978B2 (en) * 2017-11-01 2022-08-30 小林製薬株式会社 Compositions containing D-chiro-inositol
JP7450324B2 (en) * 2017-11-01 2024-03-15 小林製薬株式会社 Composition containing D-chiro-inositol
JP7127979B2 (en) * 2017-11-01 2022-08-30 小林製薬株式会社 Compositions containing D-chiro-inositol
CN111812318A (en) * 2020-06-28 2020-10-23 蒋松 New application of blood inositol as kidney prognosis diagnosis marker of diabetic nephropathy patient

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308627A (en) * 1990-08-07 1994-05-03 Umbdenstock Jr Anthony J Nutritional supplement for optimizing cellular health
TW282398B (en) * 1993-12-22 1996-08-01 Bristol Myers Squibb Co

Also Published As

Publication number Publication date
AU4802800A (en) 2000-11-10
JP2002542295A (en) 2002-12-10
EP1173188A2 (en) 2002-01-23
CA2371055A1 (en) 2000-11-02
WO2000064454A3 (en) 2001-04-12
WO2000064454A9 (en) 2002-04-04
WO2000064454A2 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
Salau et al. Vanillin and vanillic acid modulate antioxidant defense system via amelioration of metabolic complications linked to Fe 2+-induced brain tissues damage
Lee et al. Hydrogen sulfide‐releasing NSAIDs attenuate neuroinflammation induced by microglial and astrocytic activation
Surh et al. Role of Nrf2-mediated heme oxygenase-1 upregulation in adaptive survival response to nitrosative stress
BRPI0609393B8 (en) uses of an 11-deoxy-prostaglandin compound
Steinritz et al. Medical documentation, bioanalytical evidence of an accidental human exposure to sulfur mustard and general therapy recommendations
BRPI0609121B8 (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon in position 2
CR10032A (en) SOLID PREPARATION
Bishnoi et al. Protective effect of curcumin and its combination with piperine (bioavailability enhancer) against haloperidol-associated neurotoxicity: cellular and neurochemical evidence
BR0114927A (en) Substantially non-aqueous pharmaceutical gel composition for skin application, and use of the composition
DE60325379D1 (en) Composition containing 6-Ä3- (1-adamantyl) -4-methoxyphenyl-2-naphthanoic acid for the treatment of dermatological diseases
BRPI0512352A (en) 3-aminocyclopentanecarboxamides as chemokine receptor modulators
BR0312913A (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising the same
BRPI0611717A2 (en) compound, pharmaceutical composition and use of the compound
BR0308613A (en) Combination of Organic Compounds
BRPI0810956A8 (en) "COMPOSITION, METHOD FOR PREVENTIVE OR CURATIVE CONTROL AND USE OF COMPOSITION"
MA34640B1 (en) PHARMACEUTICAL COMPOSITION, METHODS OF TREATMENT AND USES THEREOF
BRPI0520669A2 (en) pharmaceutical dosage that reduces the effect of food found for atorvastatin administration
BR0010014A (en) Pharmaceutical composition comprising an inositol and a metal ion to improve insulin sensitivity and glucose metabolism
BR112022009189A2 (en) METHODS TO REDUCE THE RISK OF CARDIOVASCULAR EVENT IN A SUBJECT WITH ATRIAL FIBRILLATION AND/OR ATRIAL PALPITATION
Michalke Review about the manganese speciation project related to neurodegeneration: An analytical chemistry approach to increase the knowledge about manganese related parkinsonian symptoms
BRPI0620229B8 (en) pharmaceutical formulations and production processes of said formulations
WO2010042886A3 (en) Pyrones for the treatment of metabolic disorders
WO2008063768A3 (en) Compositions and methods for treating metabolic diseases
Khan et al. Reduction of oxidative stress through activating the Nrf2 mediated HO-1 antioxidant efficacy signaling pathway by MS15, an antimicrobial peptide from Bacillus velezensis
BR0312921A (en) Composition comprising hmg-coa reductase inhibitor

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]